CN1142780C - 药用组合物 - Google Patents

药用组合物 Download PDF

Info

Publication number
CN1142780C
CN1142780C CNB971949611A CN97194961A CN1142780C CN 1142780 C CN1142780 C CN 1142780C CN B971949611 A CNB971949611 A CN B971949611A CN 97194961 A CN97194961 A CN 97194961A CN 1142780 C CN1142780 C CN 1142780C
Authority
CN
China
Prior art keywords
weight
preparation
methocel
hydroxypropyl emthylcellulose
premium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB971949611A
Other languages
English (en)
Chinese (zh)
Other versions
CN1219879A (zh
Inventor
Bv
B·V·帕里克
��������ķ������
R·J·蒂姆科
W·J·阿迪克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10794541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1142780(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of CN1219879A publication Critical patent/CN1219879A/zh
Application granted granted Critical
Publication of CN1142780C publication Critical patent/CN1142780C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CNB971949611A 1996-05-31 1997-05-27 药用组合物 Expired - Lifetime CN1142780C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9611328.7 1996-05-31
GBGB9611328.7A GB9611328D0 (en) 1996-05-31 1996-05-31 Pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100033798A Division CN1511532A (zh) 1996-05-31 1997-05-27 药用组合物

Publications (2)

Publication Number Publication Date
CN1219879A CN1219879A (zh) 1999-06-16
CN1142780C true CN1142780C (zh) 2004-03-24

Family

ID=10794541

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2004100033798A Pending CN1511532A (zh) 1996-05-31 1997-05-27 药用组合物
CNA2006101016820A Pending CN101006985A (zh) 1996-05-31 1997-05-27 药用组合物
CNB971949611A Expired - Lifetime CN1142780C (zh) 1996-05-31 1997-05-27 药用组合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CNA2004100033798A Pending CN1511532A (zh) 1996-05-31 1997-05-27 药用组合物
CNA2006101016820A Pending CN101006985A (zh) 1996-05-31 1997-05-27 药用组合物

Country Status (31)

Country Link
EP (1) EP0907364B1 (OSRAM)
JP (5) JP2000511170A (OSRAM)
CN (3) CN1511532A (OSRAM)
AR (1) AR003662A1 (OSRAM)
AT (1) ATE222105T1 (OSRAM)
AU (1) AU727219B2 (OSRAM)
BR (1) BR9709271A (OSRAM)
CA (1) CA2251944C (OSRAM)
CZ (1) CZ293760B6 (OSRAM)
DE (1) DE69714739T2 (OSRAM)
DK (1) DK0907364T3 (OSRAM)
EG (1) EG24118A (OSRAM)
ES (1) ES2182079T3 (OSRAM)
GB (2) GB9611328D0 (OSRAM)
HR (1) HRP970299B1 (OSRAM)
HU (1) HU225152B1 (OSRAM)
ID (1) ID18352A (OSRAM)
IL (1) IL127222A (OSRAM)
MY (1) MY120120A (OSRAM)
NO (1) NO327801B1 (OSRAM)
NZ (1) NZ332198A (OSRAM)
PL (1) PL189887B1 (OSRAM)
PT (1) PT907364E (OSRAM)
RU (1) RU2201754C2 (OSRAM)
SI (1) SI0907364T1 (OSRAM)
SK (1) SK284131B6 (OSRAM)
TR (1) TR199802483T2 (OSRAM)
TW (1) TW550076B (OSRAM)
UA (1) UA50772C2 (OSRAM)
WO (1) WO1997045124A1 (OSRAM)
ZA (1) ZA974735B (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0003126D0 (sv) 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
KR20040100835A (ko) 2001-02-15 2004-12-02 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
JP3624954B1 (ja) * 2001-11-07 2005-03-02 藤沢薬品工業株式会社 分散不良薬物の溶出性を改善する方法
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
WO2007086079A2 (en) 2006-01-25 2007-08-02 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
PT1958617E (pt) 2007-02-14 2010-10-28 Lesvi Laboratorios Sl Composições farmacêuticas contendo fumarato de quetiapina
EP2131817A2 (en) 2007-03-09 2009-12-16 Synthon B.V. Pharmaceutical composition of quetiapine fumarate
US20080287418A1 (en) * 2007-05-16 2008-11-20 Astrazeneca Ab Extended Release Compositions and Methods for Their Manufacture
PT2262486E (pt) * 2008-08-01 2013-03-27 Tovarna Zdravil D D Novo Mesto Krka Composição de quetiapina
EP2153834A3 (en) 2008-08-07 2010-02-24 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
EP2373319B1 (en) * 2009-01-05 2013-07-31 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010089259A2 (en) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
EP2233130A1 (en) * 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
TWI478733B (zh) * 2009-05-13 2015-04-01 Wyeth Llc 突釋藥物釋放組合物
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
CN102218042A (zh) * 2011-05-26 2011-10-19 青岛黄海制药有限责任公司 富马酸喹硫平组合物的缓释片剂及其制备方法
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
CN102406606B (zh) * 2011-11-29 2013-01-23 海南美大制药有限公司 富马酸喹硫平脂质体固体制剂
DK2822541T3 (da) 2012-09-10 2019-01-02 Pharmathen Sa Farmaceutisk sammensætning omfattende et atypisk antipsykotisk middel og fremgangsmåde til fremstilling deraf
EP2848244A1 (en) 2013-09-16 2015-03-18 Yildiz Özsoy Erginer Extended release tablet formulations of quetiapine
EP3310344A1 (en) 2015-06-19 2018-04-25 Biotie Therapies, Inc. Controlled-release tozadenant formulations
CN106187873B (zh) * 2016-07-25 2019-11-05 宜春学院 一种芳胺基烷基氧类化合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0266707B1 (en) * 1986-11-03 1992-01-22 Schering Corporation Sustained release labetalol tablet
IE59540B1 (en) * 1987-01-09 1994-03-09 Elan Corp Sustained release capsule or tablet formulation
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
SE9003902D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Solid dosage forms of a drug
IT1256651B (it) * 1992-12-11 1995-12-12 Giancarlo Santus Composizione farmaceutica a rilascio controllato in sospensione liquida
JP3116970B2 (ja) * 1991-06-12 2000-12-11 三菱東京製薬株式会社 ペミロラストカリウムの徐放性製剤
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
CN1108150C (zh) * 1994-05-13 2003-05-14 史密丝克莱恩比彻姆公司 增加钙摄取的方法及所用的制剂

Also Published As

Publication number Publication date
AU727219B2 (en) 2000-12-07
PL189887B1 (pl) 2005-10-31
ZA974735B (en) 1997-12-01
CZ293760B6 (cs) 2004-07-14
HUP9902194A2 (hu) 2000-02-28
AR003662A1 (es) 1998-09-09
JP5888549B2 (ja) 2016-03-22
GB9709761D0 (en) 1997-07-09
ATE222105T1 (de) 2002-08-15
HUP9902194A3 (en) 2000-03-28
DE69714739D1 (de) 2002-09-19
PL330223A1 (en) 1999-05-10
EP0907364A1 (en) 1999-04-14
WO1997045124A1 (en) 1997-12-04
CA2251944C (en) 2007-04-10
TW550076B (en) 2003-09-01
JP2012031206A (ja) 2012-02-16
EP0907364B1 (en) 2002-08-14
DE69714739T2 (de) 2003-05-15
JP2014167026A (ja) 2014-09-11
UA50772C2 (uk) 2002-11-15
NO985539D0 (no) 1998-11-27
CA2251944A1 (en) 1997-12-04
SI0907364T1 (en) 2003-02-28
TR199802483T2 (xx) 1999-02-22
EG24118A (en) 2008-07-06
HRP970299A2 (en) 1998-04-30
JP2007119495A (ja) 2007-05-17
HRP970299B1 (en) 2001-12-31
SK284131B6 (sk) 2004-09-08
IL127222A (en) 2001-03-19
BR9709271A (pt) 1999-08-10
HU225152B1 (en) 2006-07-28
JP2006152006A (ja) 2006-06-15
CN1511532A (zh) 2004-07-14
NO327801B1 (no) 2009-09-28
CN101006985A (zh) 2007-08-01
CZ388098A3 (cs) 1999-02-17
ES2182079T3 (es) 2003-03-01
SK163998A3 (en) 1999-05-07
ID18352A (id) 1998-04-02
AU2967597A (en) 1998-01-05
PT907364E (pt) 2002-12-31
NZ332198A (en) 2000-05-26
NO985539L (no) 1998-11-27
IL127222A0 (en) 2000-06-01
JP2000511170A (ja) 2000-08-29
DK0907364T3 (da) 2002-11-11
MY120120A (en) 2005-09-30
RU2201754C2 (ru) 2003-04-10
CN1219879A (zh) 1999-06-16
GB9611328D0 (en) 1996-08-07

Similar Documents

Publication Publication Date Title
CN1142780C (zh) 药用组合物
US5948437A (en) Pharmaceutical compositions using thiazepine
CN101365432B (zh) 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物
CN1298317C (zh) 坦洛新片剂
CN1607947A (zh) 包含3－(3－二甲基氨基－1－乙基－2－甲基－丙基)苯酚并能提供活性成分的延迟释放的药物
CN1321088A (zh) 雷诺嗪持续释放制剂
CN1443069A (zh) 雷诺嗪缓释制剂
JP2011513408A (ja) メトホルミン及びジペプチジルペプチダーゼ−ｉｖ阻害剤の併用医薬組成物
CN1838945A (zh) 罗匹尼罗的新颖制剂
CN101442990A (zh) 消旋卡多曲的新型给药形式
CN1285738A (zh) 卡维地洛的新的口服剂型
CN1684681A (zh) 比西发定制剂
CN1867326A (zh) 加巴喷丁的缓释口服片剂及其制备方法
HK1068260A (en) Pharmaceutical compositions
CN1305379A (zh) 治疗方法
CN1552327A (zh) 口服左氧氟沙星控释药物组合物
CN1217668C (zh) 红霉素衍生物的缓释制剂
KR100484994B1 (ko) 약학조성물
HK1109063A (en) Pharmaceutical compositions
CN1564695A (zh) 药物制剂
HK1083585A (en) Bicifadine formulation
CN1933819A (zh) 包含利卡西平的口服基质制剂
HK1040060B (en) Sustained release ranolazine formulations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: SYNGENTA CO., LTD.

Free format text: FORMER NAME OR ADDRESS: ZENECA LTD

CP03 Change of name, title or address

Address after: surrey

Patentee after: Zeneca Ltd.

Address before: London, England, England

Patentee before: Zeneca Limited

ASS Succession or assignment of patent right

Owner name: ASTRAZENECA (UK) LIMITED

Free format text: FORMER OWNER: SYNGENTA CO., LTD.

Effective date: 20061229

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20061229

Address after: London, England

Patentee after: Astrazeneca UK Ltd.

Address before: surrey

Patentee before: Zeneca Ltd.

CX01 Expiry of patent term

Granted publication date: 20040324

CX01 Expiry of patent term